ArticleCureus2025
Complete Junctional Scotoma Secondary to Metastatic Melanoma: A Rapidly Progressive Presentation.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Junctional scotomas are distinctive visual field defects caused by lesions at the junction of the optic nerve and optic chiasm. The classic presentation includes ipsilateral vision loss with a contralateral superior temporal field deficit. A complete junctional scotoma involves more extensive damage, resulting in visual field loss across the entire contralateral temporal field. We present the case of a woman in her 30s with a recent diagnosis of metastatic melanoma who developed unilateral vision loss that progressed to a complete junctional scotoma within three days. Her symptoms were rapidly evolving and included trigeminal sensory changes and cranial nerve involvement. This case highlights the importance of visual field testing and thorough neurological examination in lesion localization. Although rare, metastatic tumors such as melanoma can produce aggressive neuro-ophthalmologic deficits, necessitating prompt recognition and intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.